The markets have gone ballistic on positive news of a COVID-19 vaccine, but investors are buying in all the wrong places.
The COVID-19 Vaccine Stocks to Buy Right Now
Here are the best COVID-18 vaccine stocks to buy…
The markets have gone ballistic on positive news of a COVID-19 vaccine, but investors are buying in all the wrong places.
Here are the best COVID-18 vaccine stocks to buy…
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
As of midday Thursday, we've still got no definitive result from the Nov.
3 election.
Indeed, it's still anyone's game.
And the markets are loving it.
So D.R.
appeared on FOX Business' Varney & Co.
to talk about why stocks were rallying with so much up in the air, and he even named the two stocks he thinks will be truly outstanding performers in this environment…
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
Unfortunately, the political and personal fault lines in the United States are about as raw and volatile as they've ever been. But that's a subject for another time and place.
As investors, whatever our personal politics or feelings are, now is the time to quickly come to terms with what's happening and what likely will happen in the stock market.
Because despite the market's action yesterday, it has drawn a line of its own – a "line in the sand" – and where your money is in relation to this line will make a big difference.
I'm going to show you where that line lies, because there are some dangers, no doubt, but there are also some unique profit opportunities… Full Story
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
We're less than two weeks from the Nov. 3 presidential election, and the polls are gaining clarity. Democrats are going into next month's election with a clear advantage.
FiveThirtyEight's polling average gives Democratic presidential candidate Joe Biden an 87% chance of winning the race for the White House.
And according to Real Clear Politics, betting sites on average give Biden odds of 65.1% to win.
Meanwhile, Democrats are practically guaranteed to keep control of the House of Representatives, and now have a 70% chance of taking the Senate, too, according to FiveThirtyEight.
In short, the polls say we're going to get a "blue wave." Democrats are set to take the White House and both houses of Congress.
Of course the polls have been very wrong before, so we have to remind ourselves that they tell us probabilities, not certainties…
But if the "blue team" does win, that's going to mean a different take on green energy, stimulus, anti-trust, banking and environmental regulations, and much more. Stocks will definitely be affected.
We're already seeing some sectors rise in anticipation.
So today, I'll show you how to prepare your portfolio for a "blue wave" as well as what to do if the polls end up being wrong again… Full Story
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
The market's big struggle right now, its driving narrative, is between COVID-19 and the prospects of a new, multitrillion-dollar round of stimulus.
Stocks have rebounded over the past two days, after an apparent improvement in the president's COVID-19 symptoms merited his discharge from Walter Reed National Military Medical Center.
On the coronavirus front, investors seem to have digested the bigger picture: The virus remains a severe threat and a major disruptor, but death rates are declining right now, better therapeutics are available, and several vaccine candidates are on the horizon.
Against this backdrop, we've seen no convincing signs of progress in House Speaker Nancy Pelosi's and Treasury Secretary Steven Mnuchin's negotiations over a fresh multitrillion-dollar round of stimulus. The rally lost some significant "steam" on Tuesday after U.S. Federal Reserve Chair Jerome Powell and Speaker Pelosi stressed the need for fresh stimulus, then began a much steeper dive minutes after Trump said negotiations were off until after the November election.
White House-watchers and Wall Street insiders opined that Trump's abrupt move was likely a negotiating tactic, not the end of the stimulus road.
That's established the pattern investors will have to contend with: pullbacks, driven by stimulus worries, will be promptly followed by rallies, as coronavirus fears ease. Rinse and repeat, until further notice.
I'll tell you what I think of our stimulus chances, where the market will go next, and most importantly, the one profitable play you can make right now… Full Story
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
The warm summer weather allowed people and restaurants to enjoy outdoor activities safely.
But now with the onset of fall and dropping temperatures, COVID-19 cases are resurging.
In fact, four sectors are going to be hit hard this fall and winter.
So D.R.'s showing you the six stocks to avoid now in his "Winter Survival Plan" to ensure your portfolio is well-insulated….
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
It might be too early to call it "a light at the end of the tunnel," but the quest for a novel coronavirus vaccine has entered a new, perhaps decisive phase.
We knew fairly quickly after the pandemic exploded that life in most places could never be as it was until an effective vaccine or therapy was produced.
And now we're beginning to get a picture – tentative, to be sure – of when and how that might happen.
Infectious disease expert Dr. Anthony Fauci has said he expects FDA emergency approval of some kind of vaccine by November or December of this year.
Taking it a step further, both Bill Gates and CDC Director Dr. Robert Redfield have indicated the logistics of vaccine distribution will mean life "will start to return to normal" by second and third quarters of 2021, or roughly 18 months after the social and economic devastation of this crisis started.
That seems like an awfully long time, and of course it is, but, as of now, the current "speed record" holder in the vaccine stakes belongs to Merck & Co. Inc.'s Mumpsvax.
And when I say "speed record," understand that it took nearly five years to develop Mumpsvax back in the 1960s.
For us to have an effective vaccine – any vaccine – by the end of 2020, or a little over a year since the disease emerged, would be a breathtaking, unparalleled scientific achievement.
There are dozens upon dozens of different vaccines and therapies being researched all over the world, all in different stages. The market, however, is paying the closest attention to just a few.
Aside from AstraZeneca Plc. in the United Kingdom, there are two frontrunner candidates in the United States, both in late, phase 3 clinical trials.
There's Moderna Inc., whose shares have soared as high as 400%, and Pfizer Inc., which has been rather more subdued this year, but whose vaccine candidate is a favorite in some circles for the first emergency approval.
With that said, the stock I'm going to name might not be first, but it may very well be the best… Full Story
With that said, the stock I'm going to name might not be first, but it may very well be the best...
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
Gold is near $2,000-plus all-time highs, so it's no surprise that investing legend Warren Buffett is riding alongside gold's bull run. But nobody seems to know about another class of gold plays to make right now, giving us more upside potential in this specific stock…
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
Back in my college days as a chemical engineering student, I found myself driving down to Kingsport, Tenn. I was due to start a cooperative education job at the Eastman Kodak chemical plant there.
I remember looking at the biggest chemical plant in the world with awe (13,000-plus employees at the time). Kodak sold off its chemical business – now Eastman Chemical – in 1994.
This former employer of mine has been in the news a lot lately. Through a $765 million loan from the Trump administration, it was set to revive the U.S. pharmaceutical industry.
As the news hit and the Robinhood trading crowd piled in, shares soared from $2 to more than $60 in two short days. Hope and optimism ruled.
A few days later, reality set in. The stock cratered. It's now around $10 and trending down.
This is an example of what we in the trading world call "Buy the Rumor, Sell the News."
When a rumor first hits the news feeds, it creates excitement and optimism. Stocks rise, and other traders don't want to miss out.
But things are rarely as rosy as they look at first glance. Once reality sets in, excitement gives way to reason. People start looking into the actual details of the matter.
And more often than not, it turns out that in their excitement, traders overshot.
Kodak's pharmaceutical loan was one example.
But that's small potatoes compared to what's coming next. Kodak was just one company.
This time, stock markets as a whole could be in for a "sell the news" moment. That's why today, I'm going to show you how to avoid the hype and what to do instead to come out on top… Full Story
Start the conversation
Comment on This Story Click here to cancel reply.
Or to contact Money Morning Customer Service, click here.
On Monday, a California judge ruled that Uber Technologies Inc.
(NYSE: UBER) and Lyft Inc.
(NASDAQ: LYFT) must classify their drivers as employees (as opposed to independent contractors) in a stunning preliminary injunction.
Both stocks dropped about 2% on the news.
The ruling means these companies would have to provide their drivers traditional benefits like health insurance, workers compensation, and more.
These additional benefits would become very big expenses to the already unprofitable businesses.
Lyft lost $2.6 billion in fiscal 2019.
Uber lost $8.5 billion.
And neither appear to be close to profitability so far this year…
Start the conversation